Methotrexate toxicity happens when the drug accumulates in the body beyond safe levels, starving rapidly dividing cells of the building blocks they need to survive. The most common causes are impaired kidney function, drug interactions that slow methotrexate clearance, dosing errors, and alcohol use. Understanding these triggers matters because methotrexate is one of the most widely prescribed medications for rheumatoid arthritis, psoriasis, and certain cancers, and toxicity can range from mild mouth sores to life-threatening organ failure.
How Methotrexate Works Against Your Cells
Methotrexate blocks an enzyme that converts folate into its active form, tetrahydrofolate. Your body needs tetrahydrofolate to build DNA and produce new cells. When methotrexate blocks this process, cells that divide quickly are hit hardest: the lining of your gut, blood-forming cells in the bone marrow, and cells in your liver. At the right dose, this is useful for suppressing an overactive immune system or killing cancer cells. At excessive levels, the same mechanism damages healthy tissue throughout the body.
This is why the most recognizable signs of toxicity mirror the tissues that turn over fastest. Mouth ulcers are often the earliest warning sign. Dropping blood counts (pancytopenia), liver inflammation, and kidney damage follow as exposure increases.
Kidney Function Is the Biggest Risk Factor
More than 90% of methotrexate leaves the body through the kidneys. When kidney function declines, even modestly, the drug lingers in the bloodstream longer and reaches higher concentrations. A large study of 5,648 rheumatoid arthritis patients on low-dose methotrexate found that 37.5% of those with chronic kidney disease developed blood-related toxicity, compared with just 10.7% of patients with normal kidney function.
The risk threshold is lower than many people assume. Kidney function is staged by a measurement called eGFR, with Stage 1 being normal (above 90) and higher stages reflecting worsening function. Pharmacokinetic modeling shows that standard oral methotrexate doses push blood levels past safe limits starting at Stage 2, which begins at an eGFR of 60 to 89. That’s a level many adults over 60 reach without knowing it. By Stage 3a (eGFR 45 to 59), drug concentrations significantly overshoot the risk threshold. Methotrexate is generally avoided entirely when eGFR drops below 30.
For patients with mild to moderate kidney impairment, dose reductions follow a rough scale: about 65% of the normal dose when clearance falls to 46 to 60 mL/minute, half the dose at 31 to 45, and no use below 30. This is one reason routine blood work matters so much during methotrexate treatment.
Drug Interactions That Raise Levels
Several common medications interfere with how your kidneys clear methotrexate. NSAIDs like ibuprofen and naproxen reduce the kidney’s ability to flush methotrexate through its tubules, causing levels to climb. This interaction is especially important because many people with arthritis use NSAIDs alongside methotrexate for pain relief.
Probenecid, a gout medication, directly inhibits the kidney transport system that moves methotrexate out of the body. Proton pump inhibitors (PPIs) used for acid reflux have also drawn concern, with accumulating evidence suggesting they may interfere with methotrexate clearance. Certain antibiotics, particularly penicillin-type drugs, can compete for the same excretion pathway. The combined effect of any of these with even mildly reduced kidney function can be enough to push methotrexate into toxic territory.
Accidental Daily Dosing
One of the most preventable and dangerous causes of methotrexate toxicity is taking it every day instead of once a week. Methotrexate is unusual among medications because it’s prescribed on a weekly schedule. Large datasets in both the United States and Australia have identified dosing frequency errors as a major cause of severe, sometimes fatal toxicity.
In a documented case, a patient accidentally took methotrexate daily for five days after a mistake packing her weekly pill organizer. In 12 published cases of this type of error, the most common consequences were mouth ulcers (usually the first symptom), mild liver inflammation, dangerously low blood counts, and acute kidney failure. Several deaths occurred, most from overwhelming infections after the immune system collapsed.
What makes this scenario particularly dangerous is that standard blood tests for methotrexate levels won’t catch it. With repeated daily oral doses, the drug is fully absorbed and accumulates inside cells. Serum levels may read as undetectable while intracellular concentrations are critically high.
Alcohol and Liver Damage
Methotrexate is processed partly through the liver, and combining it with alcohol increases the risk of liver injury. The largest study on this question found that drinking more than 21 units of alcohol per week (roughly 10 to 11 standard drinks) nearly doubled the rate of liver enzyme elevations. Drinking above 14 units per week was also linked to increased liver fibrosis, a precursor to scarring.
The reassuring finding is that alcohol below 14 units per week carried a very low probability (under 1%) of meaningfully increasing liver risk. Between 14 and 21 units, the probability of a clinically important increase in liver damage rose to about 33%. Above 21, it jumped to 81%. So moderate, occasional drinking appears to be low-risk for most patients, but regular heavy drinking clearly compounds the liver burden methotrexate already creates.
Genetic Variation in Folate Processing
Some people are genetically less efficient at processing folate, which can amplify methotrexate’s effects. Research has focused on variations in the MTHFR gene, which helps regulate folate metabolism. Patients carrying certain MTHFR variants showed higher rates of blood count drops, liver enzyme elevations, and gastrointestinal side effects during high-dose methotrexate treatment. A meta-analysis found a significant link between one common variant (C677T) and more severe liver toxicity in Asian populations.
The evidence is mixed, though. Some studies find no significant connection between MTHFR variants and toxicity outcomes. Genetic testing for these variants isn’t standard practice before starting methotrexate, but it may become more relevant as personalized dosing strategies develop.
How Toxicity Shows Up in the Body
Methotrexate toxicity can affect nearly every organ system, but certain patterns are characteristic. The gastrointestinal lining, which replaces itself every few days, is often the first tissue to show damage. Painful mouth sores, nausea, and diarrhea are early signals. Bone marrow suppression follows, leading to low white blood cells (raising infection risk), low platelets (raising bleeding risk), and anemia.
Liver toxicity ranges from mildly elevated enzymes on blood work to, in rare long-term cases, fibrosis and cirrhosis. Kidney damage creates a vicious cycle: methotrexate injures the kidneys, which then clear the drug even more slowly, leading to further accumulation and more damage.
In high-dose treatment protocols used for cancer, clinicians track blood levels against specific thresholds at 24, 48, and 72 hours after a dose. Levels above 10 micromoles per liter at 24 hours, above 1 at 48 hours, or above 0.1 at 72 hours signal delayed clearance and the need for rescue treatment. That rescue involves a form of active folate called leucovorin, which bypasses the enzyme methotrexate blocks and supplies cells with what they need to survive. For patients whose kidneys can’t clear the drug, an enzyme-based treatment called glucarpidase can break down methotrexate directly in the bloodstream.
Folic Acid Supplementation as Prevention
Taking folic acid alongside methotrexate is one of the simplest and most effective ways to reduce side effects. Because methotrexate works by depleting active folate, supplementing with folic acid gives the body extra raw material to partially offset the blockade. Guidelines suggest 5 to 10 mg of folic acid per week, taken on days when you don’t take methotrexate.
A randomized trial comparing 10 mg and 30 mg weekly found that the lower dose was sufficient to reduce toxicity without undermining methotrexate’s therapeutic effect. Higher doses didn’t add meaningful benefit. Folic acid supplementation won’t prevent toxicity from a major overdose or severe kidney impairment, but for day-to-day use, it significantly reduces the frequency of mouth sores, nausea, liver enzyme elevations, and blood count changes.